Attributes | Values |
---|
rdf:type
| |
Description
| - Background: Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies. Trastuzumab monotherapy results in objective responses in only similar to 15% of patients. Fulvestrant retains activity in cells overexpressing HER2 that are resistant to other endocrine treatments. This retrospective study evaluated response to fulvestrant treatment among HER2-positive patients with advanced breast cancer (ABC).
- Background: Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies. Trastuzumab monotherapy results in objective responses in only similar to 15% of patients. Fulvestrant retains activity in cells overexpressing HER2 that are resistant to other endocrine treatments. This retrospective study evaluated response to fulvestrant treatment among HER2-positive patients with advanced breast cancer (ABC). (en)
|
Title
| - Activity of fulvestrant in HER2-overexpressing advanced breast cancer
- Activity of fulvestrant in HER2-overexpressing advanced breast cancer (en)
|
skos:prefLabel
| - Activity of fulvestrant in HER2-overexpressing advanced breast cancer
- Activity of fulvestrant in HER2-overexpressing advanced breast cancer (en)
|
skos:notation
| - RIV/00064165:_____/10:4243!RIV11-MZ0-00064165
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00064165:_____/10:4243
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Advanced breast cancer; Faslodex; fulvestrant; HER2; human epidermal growth factor 2 (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Petruželka, Luboš
- Robertson, J.F.R.
- Steger, G. G.
- Barni, S.
- Gieseking, F.
- Kaufman, B.
- Neven, P.
- Nole, F.
- O\\\'Malley, F. P.
- Pritchard, K. I.
- Simon, S. D.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |